The birth of the congressional clinic
AbstractThis paper investigates the impact of mortality in the districts/states represented in key congressional groups (i.e. committees, subcommittees, and parties) on the public investment in medical research in the US. I focus on National Institutes of Health (NIH) R01 grants awarded between 1985-2002. Exploiting the recomposition of any group after congressional elections, I estimate that the composition of the House Subcommittee on Labor, Health and Human Services, Education and Related Agencies (HouS), impacts the NIH budget: a 1% increase of life-years lost because of a disease in the districts represented in HouS increases the funds for clinical research on that disease by 1.2-3.2%. I also find that this impact results from the larger bargaining power of HouS or the House majority, or both groups, in the budget process. No group significantly impacts the allocation of funds for basic research, or the allocation of funds across states.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by HAL in its series PSE Working Papers with number halshs-00564921.
Date of creation: Oct 2010
Date of revision:
Note: View the original document on HAL open archive server: http://halshs.archives-ouvertes.fr/halshs-00564921
Contact details of provider:
Web page: http://hal.archives-ouvertes.fr/
health policy ; government policy ; publicly-provided goods ; medical research ; legislative bargaining;
This paper has been announced in the following NEP Reports:
- NEP-ALL-2011-02-19 (All new papers)
- NEP-CIS-2011-02-19 (Confederation of Independent States)
- NEP-HEA-2011-02-19 (Health Economics)
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Jacob, Brian A. & Lefgren, Lars, 2011.
"The impact of research grant funding on scientific productivity,"
Journal of Public Economics,
Elsevier, vol. 95(9-10), pages 1168-1177, October.
- Brian Jacob & Lars Lefgren, 2007. "The Impact of Research Grant Funding on Scientific Productivity," NBER Working Papers 13519, National Bureau of Economic Research, Inc.
- Rodrigo Cerda, 2003. "Drugs, Market Size and Population," Documentos de Trabajo 238, Instituto de Economia. Pontificia Universidad Católica de Chile..
- Daron Acemoglu & Joshua Linn, 2004.
"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,"
Levine's Working Paper Archive
228400000000000002, David K. Levine.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, MIT Press, vol. 119(3), pages 1049-1090, August.
- Daron Acemoglu & Joshua Linn, 2003. "Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry," NBER Working Papers 10038, National Bureau of Economic Research, Inc.
- Brian Knight, 2005. "Estimating the Value of Proposal Power," American Economic Review, American Economic Association, vol. 95(5), pages 1639-1652, December.
- Erik Snowberg & Justin Wolfers & Eric Zitzewitz, 2006.
"Party Influence in Congress and the Economy,"
NBER Working Papers
12751, National Bureau of Economic Research, Inc.
- Snowberg, Erik & Wolfers, Justin & Zitzewitz, Eric, 2007. "Party Influence in Congress and the Economy," International Quarterly Journal of Political Science, now publishers, vol. 2(3), pages 277-286, August.
- Jay Bhattacharya & Mikko Packalen, 2008. "Is Medicine an Ivory Tower? Induced Innovation, Technological Opportunity, and For-Profit vs. Non-Profit Innovation," NBER Working Papers 13862, National Bureau of Economic Research, Inc.
- Frank R. Lichtenberg & Joel Waldfogel, 2003. "Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act," NBER Working Papers 9750, National Bureau of Economic Research, Inc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (CCSD).
If references are entirely missing, you can add them using this form.